Cox-2 inhibitor

Phase 3Small molecule

SSeoul National University Hospital

Cox-2 inhibitor is one of 25 small molecule programs targeting Arthropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ArthropathyActive, not recruiting

Gastric CancerActive, not recruiting

ArthropathyPhase 3

Active, not recruiting

Gastric CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

714 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Fluoropyrimidine

Roche

Phase 3

1 2

Cox-2 inhibitor

SSeoul National University Hospital

Phase 3

1 3

Gemzar

Johnson & Johnson

Preclinical

—4

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

3 5

S1,

CChinese Academy of Medical Sciences

Preclinical

17 6

PD-1 Inhibitor

Johnson & Johnson

Preclinical

3 7

Induction Phase1

Genmab

Preclinical

1 8

Glutamine

Sanofi

Preclinical

1 9

Human Albumin

TTonghua Anrate Biopharmaceutical Co., Ltd.

Preclinical

1 10

CEA-Targeted CAR-T Cells

CChongqing Precision Biotech Co., Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Post Operative Pain1 trial

Comparing Postoperative Pain Following COX-2 and Prostanoids Expression

Unknown status·SSeoul National University Hospital·N/A·NCT03391570·60 enrolled

Arthropathy1 trial

Effect Observation Study of COX-2 Inhibitor to Treat Primary Hypertrophic Osteoarthropathy

Unknown status·PPeking Union Medical College Hospital·Phase 3·NCT02438709·30 enrolled

Gastric Cancer1 trial

Chemoprevention of Gastric Cancer by Intervention With Helicobacter Pylori and Cyclooxygenase Pathway

Unknown status·HHospital Authority, Hong Kong·N/A·NCT00498134·1,200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Cox-2 inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cox-2 inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cox-2 inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSeoul National University Hospital

Cox-2 inhibitor

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Post Operative Pain1 trial

Arthropathy1 trial

Gastric Cancer1 trial

References

Drug Info

Quick Facts

Related News